Depo-Provera Brain and Spine Tumors Lawsuit
- A recent study in the British Medical Journal indicates 450% increase in risk in developing a meningioma tumor for women who use Depo-Provera.
- Pfizer has already made changes to its Depo-Provera label in Europe, including a specific warning about the risk of meningiomas, but not in the United States. Patients in Europe are receiving more detailed information about potential risks than the US patients.
- There are approximately 3 million prescriptions for Depo-Provera filled annually in the United States. Based on the increased risk in developing a meningioma tumor, approximately 20,000 women may have been affected.
Our Depo-Provera Attorneys will review your case for FREE.
You could be entitled to compensation for injury from use of Depo-Provera!
Risk of injuries related to use of Depo-Provera:
Recent findings suggest a potential link between prolonged use of Depo-Provera and an increased risk of developing meningiomas—a type of tumor that forms in the protective membranes surrounding the brain and spinal cord.
Meningioma is not usually cancerous but may press on the brain, nerves or vessels and may result in disability or become life-threatening. Meningiomas are usually slow-growing tumors and may exist in the brain for many years without symptoms before being diagnosed.
The injuries linked to Depo-Provera are:
- Meningioma brain tumor
- Pseudotumor Cerebri
- Meningioma spine tumor
Meningiomas are categorized into three different grades:
· Grade I: A totally non-cancerous meningioma that grows very slowly, accounting for 8 out of 10 cases.
· Grade II: Non-cancerous but more rapidly growing, making treatment more difficult.
· Grade III: Malignant (cancerous) tumors that grow fast and aggressively, comprising less than 2% of cases.
Treatment for a symptomatic intracranial meningioma usually involves a highly invasive brain surgery known as a craniotomy, where a portion of the skull is removed to access the brain and meninges. Due to the tumor’s sensitive location, complete removal may be risky and technically challenging, often necessitating additional treatments such as radiation therapy or chemotherapy.
Do I Qualify to Join the Depo-Provera Tumor Lawsuit?
Our law firm is currently accepting Depo Provera lawsuits from anyone who used this drug at least two times and was later diagnosed with a brain tumor or spine tumor.
Use of Depo-Provera: You or your loved one must have received Depo-Provera or Depo-SubQ Provera, at least twice before meningioma or brain tumor diagnosis.
Recent Use: You must have used Depo-Provera at least once in the 12 months prior to your diagnosis. This helps to demonstrate a timely link between taking Depo-Provera and the onset of symptoms.
Diagnosis of Meningioma: A confirmed meningioma diagnosis is required, typically identified through imaging tests like an MRI or CT scan, within one year after using Depo-Provera or Depo-SubQ Provera birth control shot. This diagnosis is crucial as it establishes the medical condition tied to the drug.
There’s only a limited amount of time to file a Depo-Provera brain tumor lawsuit due to state laws called statutes of limitations. Once the deadline in your case passes, you won’t be able to take legal action and pursue a settlement for your injuries again. Click on the Red "Send My Documents" button to contact us. We will evaluate your claim for free.
Introduced in 1992 Depo-Provera is a widely used birth control injection that has gained popularity due to its effectiveness and convenience.
Depo-Provera is the brand name for medroxyprogesterone acetate. Often called the birth control shot, is an injectable form of contraception for women. It is administered by injection (in the arm or butt) every three months and provides a highly effective, long-lasting option without the need for daily attention, as long as it is taken on schedule.
Depo-Provera contains a special type of synthetic hormone called progestin. This hormone prevents pregnancy by blocking the release of eggs during ovulation and thickening cervical mucus to prevent sperm from reaching the egg It also thickens the mucus lining of the cervix which helps keep out sperm.
The injection releases a steady dose of medroxyprogesterone into the bloodstream, maintaining contraceptive protection for approximately 12 weeks.
Depo-Provera may be used by nearly 25% of women at some point during their lives, many of whom will use the medication for longer than one year.
Recent findings suggest a potential link between prolonged use of Depo-Provera and an increased risk of developing meningiomas.
British Medical Journal Finds Link Between Prolonged Use of Depo-Provera and Increase Risk of Brain Tumors:
A study published in the British Medical Journal found that prolonged use of Depo-Provera causes a significant increase in the risk of developing meningioma brain tumors. The study found that women who used Depo-Provera were more than 5 times more likely to be diagnosed with meningiomas compared to women who never used the birth control shot.
In March 2024, a significant new scientific study was released which found a clear link between the use of Depo-Provera and the development of specific type of brain tumor called a meningioma. The study was published in the British Medical Journal, a very prominent and well-respected medical journal.
The study investigated the relationship between the use of certain hormone medications, known as progestogens (the active ingredient in Dep-Provers), and the risk of developing a type of brain tumor called meningioma. The research focused on a variety of progestogens, analyzing data which included women who had undergone surgery for meningioma.
The research utilized data from 18,061 women who underwent surgery for meningioma between 2009 and 2018. Of the women who had surgery, over 2,500 were exposed to hormones used in birth control.
The researchers concluded that prolonged use of hormones used in Depo-Provera (medrogestone, medroxyprogesterone acetate, and promegestone) was found to increase the risk of intracranial meningioma.
Previous Studies put Pfizer on Notice of a Problem
In 1983, a study published in European Journal of Cancer & Clinical Oncology identified the presence of a high concentration of progesterone receptors in human meningioma cells.
This means that progesterone could influence the growth of meningiomas tumors.
The study helps demonstrate that prolonged use of progesterone-based drugs like Depo Provera may significantly increase the risk of meningiomas should have been a concern as far back as 1983.
In 1991, a study published in Journal of Neurosurgery, explored the effects of mifepristone, an anti-progesterone agent, on meningiomas tumors.
This agent blocks the progesterone (like Depo-Provera) and inhibits the action of progesterone on tumor cells.
The study demonstrated that mifepristone treatment resulted in a backward effect on brain tumor growth. This means that blocking progesterone receptors could stop tumor growth. This shows that the theory that progesterone (Depo-Provera) plays a significant role in meningioma tumor growth.
Pfizer Has a Duty to Warn its customers and Doctors
Pharmaceutical companies, such as Pfizer, are legally obligated to ensure that their products are reasonably safe for consumers and to provide clear and accurate warnings about potential risks associated with their use.
Patients and healthcare providers rely on the safety information provided by manufacturers when making decisions about medication use.
In the case of Depo-Provera, the link between the drug and meningiomas was not listed as a potential risk or side effect in the drug’s warning label.
If Pfizer had disclosed the increased risk of meningioma associated with their product, what would have been the outcome? Simply put: fewer sales for Pfizer. Many patients—likely most—would have opted for alternative contraceptive methods, and healthcare providers would have exercised greater caution in prescribing the drug, especially for long-term use.
Transparency about these risks could have significantly altered the decision-making process for both patients and physicians, ultimately leading to different, and apparently safer, choices.
There are so many birth control options. Why pick the one that could cause you a brain tumor?
FREE Evaluation for your
Depo-Provera Tumor Case
What You Can Do & How We Can Help
Aaronson & Rash, PLLC was founded in 2005. We handle cases nationwide from our principal office in Houston, Texas.
At Aaronson and Rash, PLLC, our attorneys are here to help you. We have over 40 years of combined experience in personal injury, environmental disasters, defective products, pharmaceutical litigation, and toxic exposure cases. Our legal team is ready to work with you and your family as we fight for the maximum compensation you deserve.
Bilingual staff is available for Spanish clients. At Aaronson & Rash, we believe that everyone deserves an experienced attorney, no matter their financial circumstances. That’s why we only accept cases on a contingency fee basis. Rather than an hourly legal fee, a contingency fee arrangement means that the attorney will not receive any payment until the completion of the lawsuit and only if the suit is successful.
We offer 100% free and confidential case evaluations. If you would like more information, click on the CONTACT button or call our offices at 844 THE LAW 4 (844-843-5294) for a FREE CASE EVALUATION from our experienced attorneys.
Justice for Depo-Provera Victims and Their Families
Important: There are strict time deadlines for filing your claim, ACT NOW
The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship. These listings are not a guarantee or prediction of the outcome of any other claims or lawsuits. Aaronson and Rash, PLLC, 6200 Savoy, STE 950, Houston, TX 77036 Privacy policy Copyright © 2018 Aaronson and Rash PLLC - All Rights Reserved.
Aaronson and Rash PLLC Principal Office is in Houston, TX. While this firm maintains joint responsibility, most cases of this type are referred to other attorneys for principal responsibility. Aaronson and Rash are the attorneys responsible for the content of this advertisement. The hiring of a lawyer is an important decision that should not be based solely upon advertisements. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers. This advertisement is not intended for residents of AL, AR, AZ, HI, IN, IA, MS, RI, SC, SD, TN, FL, NY, and KY. Prior results do not guarantee a similar outcome. Contingent attorneys’ fee refers only to those fees charged by attorneys for their legal services. Such fees are not permitted in all types of cases. Court costs and other additional expenses of legal action usually must be paid by the client. The percentage fee will be computed before or after expenses are deducted from the recovery in accordance with state laws. Clients are responsible for their own unpaid medical bills. Client may have to pay opposing party’s attorney fees and costs in the event of a loss. Anyone considering a lawyer should independently investigate the lawyer’s credentials and ability, and not rely upon advertisement or self-proclaimed expertise.
By checking Submit I understand that this is an attorney advertisement and that I consent to being contacted by the law firm by email, SMS and voice telephone. By clicking Submit, you agree to send your info to Aaronson & Rash PLLC who agrees to use it according to their privacy policy.